Presentation is loading. Please wait.

Presentation is loading. Please wait.

R&D Financing by the Bill & Melinda Gates Foundation PRESENTED BY Neil McDonnell, Pharm.D. January 12, 2009 WHO Expert Working Group on R&D Financing.

Similar presentations


Presentation on theme: "R&D Financing by the Bill & Melinda Gates Foundation PRESENTED BY Neil McDonnell, Pharm.D. January 12, 2009 WHO Expert Working Group on R&D Financing."— Presentation transcript:

1 R&D Financing by the Bill & Melinda Gates Foundation PRESENTED BY Neil McDonnell, Pharm.D. January 12, 2009 WHO Expert Working Group on R&D Financing

2 Gates Foundation Mission To ensure that life-saving advances in health are developed & shared with those who need them the most. (Photo, chart, or graph here) © 2009 Bill & Melinda Gates Foundation | 2

3 How We Prioritize Our Work Greatest burden The areas that cause widespread illness and death: infectious diseases, undernutrition, and reproductive maternal, neonatal, and child health Widest imbalance Problems that disproportionately affect poor countries Gaps in attention Fill in areas receiving inadequate attention and resources Benefit the most people Prevention has the greatest impact – focus on vaccines and other prevention strategies, micronutrient deficiencies Be willing to take risks Innovation requires accepting risks © 2009 Bill & Melinda Gates Foundation | 3

4 DALYs by Cause, Low Income Countries © 2009 Bill & Melinda Gates Foundation | 4 Non-Foundation Priorities: 43% Foundation Priorities: 57%

5 How We Prioritize Our Work Greatest burden The areas that cause widespread illness and death: infectious diseases, undernutrition, and reproductive maternal, neonatal, and child health Widest imbalance Problems that disproportionately affect poor countries Gaps in attention Fill in areas receiving inadequate attention and resources Benefit the most people Prevention has the greatest impact – focus on vaccines and other prevention strategies, micronutrient deficiencies Be willing to take risks Innovation requires accepting risks © 2009 Bill & Melinda Gates Foundation | 5

6 Foundation Support for Discovery, Development, and Delivery DiscoveryDevelopmentDelivery © 2009 Bill & Melinda Gates Foundation | 6 Appropriate Uptake and Use Global Health Impact

7 Gates Foundation Support for Drugs and Vaccines in Late-Stage Preclinical or Clinical Development Product ClassCandidates HIV (Vaccines)13 HIV (Non-Vaccine Prevention)9 TB (Vaccines) 6 TB (drugs) 2 Malaria (vaccines) 10 Malaria (drugs) 6 Pneumonia (vaccines) 5 Diarrhea (vaccines)11 Diarrhea (drugs)1 Dengue Fever1 Visceral Leishmaniasis3 Human African Trypanosomiasis2 Hookworm2 Japanese Encephalitis1 Human Papillomavirus1 Product/Platform Candidates4 Total77 © 2009 Bill & Melinda Gates Foundation | 7

8 Product Development Partnerships Supported by the Gates Foundation © 2009 Bill & Melinda Gates Foundation | 8 Diarrhea International Vaccine Institute Enteric Vaccine Initiative Advancing Rotavirus Vaccine Development HIV/AIDS International AIDS Vaccine Initiative International Partnership for Microbicides Malaria Medicines for Malaria Venture Malaria Vaccine Initiative NTD Dengue: Pediatric Dengue Vaccine Initiative Hookworm: Human Hookworm Vaccine Initiative Leishmaniasis: Infectious Disease Research Institute Trypanosomiasis: UNC Consortium for Parasitic Drug Development Multiple: Drugs for Neglected Diseases Initiative Respiratory Infection Influenza Vaccine Development Program Meningitis Vaccine Project Pneumococcal Vaccine Development Program TB Aeras Global TB Vaccine Foundation Global Alliance for TB Drug Development Cross-Cutting Foundation for Innovative New Diagnostics Innovative Vector Control Consortium Institute for One World Health

9 Global Health Program Payout © 2008 Bill & Melinda Gates Foundation

10 The Need for R&D in Global Health Guaranteed obsolescence in infectious diseases We need for newer, better methods of prevention Many disease for which no effective treatment or prevention is available Innovation is required to meet these challenges Financing innovation requires a willingness to make extremely risky investments © 2008 Bill & Melinda Gates Foundation

11 Providing Access to Medicines and Vaccines for the Poor – Focus on R & D Governments Support for basic research Support innovative finance mechanisms designed to stimulate R&D Support for funds such as the Global Fund, GAVI, UNITAID, etc. Industry Research, development, and manufacturing to addresses global disease burden and neglected diseases Access Plans © 2008 Bill & Melinda Gates Foundation

12 Providing Access to Medicines and Vaccines for the Poor – Focus on R & D Foundations Work in defined niches Support innovation and development of new health solutions Operating at the interface between governments, the private sector, and other interested parties De-risking subsequent investments by the public and private sectors © 2008 Bill & Melinda Gates Foundation

13 Research Institute Academic Lab Biotech Company Govern- ment Lab Pharma Biotech Company Pharma Many players to incentivize in R&D, final common pathway through industry © 2008 Bill & Melinda Gates Foundation Academic Lab Biotech Govern- ment Lab Pharma Research Institute Pharma Biotech Govern- ment Lab Discovery Development Product Approval Introduction Biotech Pharma

14 Stimulating Global Health R&D We need incentives for governments, foundations, and a broad cross section of industries to participate in the R&D effort We need to identify novel mechanisms to fund global health R&D and new policies that encourage more R&D. We have to be willing to take risks © 2008 Bill & Melinda Gates Foundation


Download ppt "R&D Financing by the Bill & Melinda Gates Foundation PRESENTED BY Neil McDonnell, Pharm.D. January 12, 2009 WHO Expert Working Group on R&D Financing."

Similar presentations


Ads by Google